• Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
Immunicum
  • Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
You are here:HomeInvestorsCorporate GovernanceSenior Executives

Investors

  • Overview
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • Subscribe
  • Events & Presentations
  • Corporate Governance
    • Articles of Association
    • General meeting
    • Board of directors
    • Corporate governance reports
    • Senior Executives
    • Nomination Committee
    • Remuneration and the remuneration committee
    • Auditors and audit committee
    • Scientific committee
    • Scientific Advisory Board
  • Shareholder & Stock Info
    • Shareholders
    • Insider
    • Investment calculator
    • Share price look-up
  • Analyst Coverage
  • Financial Reports
  • Financial calendar
  • Secured Rights issue 2018
  • Secured Rights issue 2017
  • Downloads

Senior Executives

  • Sven Rohmann

    Chief Executive Officer

    MD, PhD, Executive MBA, J Gutenberg University, Mainz, Germany and Erasmus University, Rotterdam, Netherlands Born: 1962

    Dr. Rohmann received his medical degree from the University of Mainz, Germany; his Ph.D. in medicine from the Erasmus University in Rotterdam, the Netherlands; and an Executive MBA from the Kellogg School of Management in the USA. Sven brings more than three decades of experience as a successful executive in the industry, recently as acting CEO for Oasmia Pharmaceuticals, as founding CEO at Ganymed Pharmaceuticals, and senior management roles at Novartis and Merck KGaA.

  • ERIK MANTING

    CHIEF BUSINESS OFFICER (CBO) AND DEPUTY CEO

    Shares: 530,824 Ph.D. in Molecular Microbiology and M.Sc. in Medical Biology Born: 1971

    Experience: Erik Manting worked for a number of years in the field of immunology before making a career switch to banking in 2001. He spent the next 15 years in different commercial and management roles and his last five years in banking as Executive Director Corporate Finance at Kempen & Co, an investment bank with a focus on Life Sciences & Healthcare. He joined DCprime in 2017, first as business development consultant, and from March 2018 as CEO until the combination with Immunicum in December 2020.

    Ongoing engagements: Supervisory board member Synerkine Pharma BV, Independent Director Transcode Therapeutics Inc.

  • JEROEN ROVERS

    MANAGING DIRECTOR OF DCPRIME

    M.D., Ph.D., Dr. Rovers has a medical degree from Leiden University and a Ph.D. in Surgical Oncology Born: 1970

    Experience: Jeroen Rovers trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 20 years he worked in different academic institutes and companies, such as Wyeth and Organon and most recently at Kiadis Pharma where he held the role as Chief Medical Officer. Most of the products he worked on are related to oncology, haematology and transplantation. He joined DCprime as Chief Medical Officer in 2018 and is Managing Director of DCprime after the merger with Immunicum in December 2020.

  • Alex Karlsson-Parra

    Chief Scientific Officer

    Shares: 621,736 (private and through related persons’ holdings), 184,000 (warrants) M.D., Ph.D. Adjunct Professor in Clinical Immunology, Uppsala University, Sweden Born: 1950

    Experience: Alex Karlsson-Parra, MD, PhD has over 20 years of experience within transplantation immunology. In addition to his position as Co-Founder and CSO at Immunicum, he also serves as Associate Professor in Clinical Immunology at Uppsala University, Uppsala, Sweden, with special expertise in transplantation immunology and cancer immunotherapy and is former chairman of the Swedish Expert Group for Clinical immunology. Dr. Karlsson-Parra was awarded the Athena Prize, the Swedish healthcare´s most prestigious award for clinical research, in 2014. Prior to his current positions, he served as Associate Professor and Senior Physician at the Department of Clinical Immunology at Sahlgrenska University Hospital, Gothenburg, Sweden and Uppsala University Hospital, Sweden.

    Ongoing engagements: –

    Past engagements during the last five (5) years: Board member of Immunicum.

  • Sijme Zeilemaker

    Chief Operating Officer

    Shares: 13,302, 400,000 (warrants) MSc Biomedical Sciences, Leiden University Born: 1987

    Experience: Sijme Zeilemaker joins Immunicum having most recently served as Director Business Development at InteRNA Technologies where he supported the preclinical oncology company in connecting with pharmaceutical and biotechnology companies, licensing technologies and exploring grant opportunities. Sijme also served as Head of Business for 2-BBB Medicines and Business Development Manager for to-BBB technologies where he provided partnering support and attracted funding.

    Ongoing engagements: –

    Past engagements during the last five (5) years: –

  • Peter Hein

    Interim CFO

    MSc in Business and Economics, Stockholm University Born: 1957

    Experience: Peter Hein has extensive experience from leading positions in the life science industry. He served as CFO at Q-Med, Biolipox (Orexo) and BioArctic AB. He has also been CEO and CFO for the retail chain Granngården. Peter Hein also brings experience in management and finance from Ericsson and Swedish Match.

    Ongoing engagements: Savelend Credit Group, Lacolle AB

    Past engagements during the last five (5) years: Genovis AB

  • Peter Suenaert

    Chief Medical Officer

    Shares: 25,000 MD, PhD in Medical Sciences from Leuven University, Belgium Born: 1968

    Experience: Peter has held a number of global development positions in the pharmaceutical industry including Senior Medical Scientist Haemat/Oncology Late Phase Development at Amgen (UK), Medical Director Early Clinical Development at GSK Bio (Cancer Immunotherapeutics, BE)), Global Oncology Lead at Glenmark Pharma (Immunotherapeutics, UK), Chief Medical Officer at Immunicum AB and Vice-President Global Clinical Development at AgenTus Therapeutics (BE). He is a board-certified medical doctor in Gastroenterology, qualified in Digestive Oncology and has a PhD in Medical Sciences from Leuven University, Belgium. He completed a post-doc at McGill University Health Center, Canada, and at Institut Gustave Roussy, France, and was on staff as Clinical Head Digestive Oncology at the University Hospital Antwerp before joining the pharmaceutical industry.

    Ongoing engagements:  SparkClin BV (consultancy company, BE), co-founder and managing director since 23 Jan 2020 and Medical Advisor to AgenTus Therapeutics Inc., Lexington (MA), USA since 05/2020

  • Sharon Longhurst

    Head of CMC

    Shares: 8,493. 180,000 (warrants) Ph.D. in Virology, University of Warwick Born: 1969

    Experience: Sharon Longhurst has over 15 years in leading CMC efforts in small and medium sized organization. Sharon Longhurst joins Immunicum from her previous position as Senior CMC Manager at Akari Therapeutics, where she was responsible for all aspects of CMC, including clinical supply and distribution. Prior to that, Sharon spent 5 years as Principal Consultant of CMC at Parexel Consulting. From 2005–2011, she was a Pharmaceutical Assessor at MHRA in London in the biologics/biotechnology unit and provided national and EU scientific advice for Advance Therapy Medicinal Products (ATMPs) for cell and gene therapy.

    Ongoing engagements: Member of the Board, Idogen AB; May 2020 – present day

     

  • Margareth Jorvid

    Head of Regulatory and QA

    Shares: 19,418. 230,644 (warrants) MSc Pharm, Uppsala University, MSc MTRA, Cranfield University, MBA, Stockholm School of Economics Born: 1961

    Experience: Margareth Jorvid has over 30 years’ experience in Regulatory Affairs for pharmaceuticals and has worked at the Medical Products Agency (MPA), as well as in large and small pharmaceutical companies such as Roussel Nordiska, Hoechst Marion Roussel (Stockholm and Paris, France) and Neopharma. Since 2006, consultant in regulatory affairs and quality assurance for pharmaceuticals and medical devices, as CEO of Methra Uppsala AB, LSM group. She is a Fellow and Honorary Life Member of TOPRA (The Organisation for Professionals in Regulatory Affairs), board member and TOPRA President 2005-2006.

    Ongoing engagements: –

    Past engagements during the last five (5) years: –

Press releases

Choose which language you would like to receive the press release in:

Swedish English
Contact us

Östermalmstorg 5
114 42 Stockholm
Sweden

Telephone

+46 (0)8 732 8400

Email

info@immunicum.com

For information about personal data processing at Immunicum, please see Immunicum´s Integrity Policy

Social
Links
  • Sitemap
  • Integrity and Cookie Policy

© 2002-2021 Immunicum AB. All rights reserved.

Designer mkmedia
To top

We use cookies to improve the user experience on Immunicum. Read more about Cookies

Approve